Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer
Leptomeningeal Disease

Interventions: Drug: Tucatinib
Drug: Trastuzumab
Drug: Capecitabine

First Posted Date: 2018-04-18

Last Posted Date: 2024-01-11

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 17

Registration Number: NCT03501979

Locations: 🇺🇸
University of Michigan-, Ann Arbor, Michigan, United States
🇺🇸
UCSF-Mission Bay, San Francisco, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 6 locations

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Capecitabine
Drug: Nivolumab

First Posted Date: 2018-04-04

Last Posted Date: 2024-12-03

Lead Sponsor: Georgetown University

Target Recruit Count: 45

Registration Number: NCT03487666

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 1 locations

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Breast Cancer

Interventions: Drug: Entinostat
Drug: Capecitabine

First Posted Date: 2018-03-22

Last Posted Date: 2022-11-01

Lead Sponsor: University of Virginia

Target Recruit Count: 13

Registration Number: NCT03473639

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer
GastroEsophageal Cancer

Interventions: Biological: SHR-1210
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Apatinib

First Posted Date: 2018-03-21

Last Posted Date: 2024-01-11

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 67

Registration Number: NCT03472365

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

Interventions: Drug: Tislelizumab
Drug: Cisplatin
Drug: Oxaliplatin
Drug: 5-FU
Drug: Capecitabine

First Posted Date: 2018-03-19

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 30

Registration Number: NCT03469557

Locations: 🇨🇳
Fifth Medical Center of Pla General Hospital, Beijing, Beijing, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 3 locations